- Home
- OLO vs RCUS Comparison
OLO vs RCUS Comparison
Compare OLO & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLO
- RCUS
- Stock Information
- Founded
- OLO 2005
- RCUS 2015
- Country
- OLO United States
- RCUS United States
- Employees
- OLO N/A
- RCUS N/A
- Industry
- OLO Major Banks
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- OLO Finance
- RCUS Health Care
- Exchange
- OLO Nasdaq
- RCUS Nasdaq
- Market Cap
- OLO 1.2B
- RCUS 1.2B
- IPO Year
- OLO 2021
- RCUS 2018
- Fundamental
- Price
- OLO $7.23
- RCUS $13.42
- Analyst Decision
- OLO Buy
- RCUS Buy
- Analyst Count
- OLO 3
- RCUS 12
- Target Price
- OLO $8.67
- RCUS $34.50
- AVG Volume (30 Days)
- OLO 1.1M
- RCUS 632.2K
- Earning Date
- OLO 02-19-2025
- RCUS 02-19-2025
- Dividend Yield
- OLO N/A
- RCUS N/A
- EPS Growth
- OLO N/A
- RCUS N/A
- EPS
- OLO N/A
- RCUS N/A
- Revenue
- OLO $271,872,000.00
- RCUS $263,000,000.00
- Revenue This Year
- OLO $24.59
- RCUS $127.65
- Revenue Next Year
- OLO $15.65
- RCUS N/A
- P/E Ratio
- OLO N/A
- RCUS N/A
- Revenue Growth
- OLO 26.41
- RCUS 119.17
- 52 Week Low
- OLO $4.20
- RCUS $12.53
- 52 Week High
- OLO $8.35
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- OLO 46.70
- RCUS 39.20
- Support Level
- OLO $7.08
- RCUS $12.83
- Resistance Level
- OLO $7.60
- RCUS $13.56
- Average True Range (ATR)
- OLO 0.28
- RCUS 0.58
- MACD
- OLO -0.04
- RCUS -0.01
- Stochastic Oscillator
- OLO 31.55
- RCUS 35.86
About OLO Olo Inc.
Olo Inc is an open Software as a Service platform for restaurants. Its platform powers restaurant brands' on-demand digital commerce operations, enabling digital ordering, delivery, front-of-house management, and payments, while further strengthening and enhancing restaurants' direct guest relationships. The company generates revenue from providing its customers access to its platform.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.